Abstract
We read with interest the randomized clinical trial by Thadhani et al. appraising the impact of an active vitamin D compound (paricalcitol) in patients with echocardiographic evidence of cardiac hypertrophy [1], as well as the accompanying editorial by Anker and von Haehling [2]. However, the study and editorial conclusions that paracalcitol did not significantly impact on left ventricular mass index or several measures of diastolic dysfunction cannot be considered reliable given the several major shortcomings of the study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
